National Institute for Health and Care Excellence (NICE) announce the approval of Nintedanib drug for the treatment of pulmonary fibrosis
Action for Pulmonary Fibrosis (APF) is very pleased that NICE has announced the approval of Nintedanib, for the treatment of patients with IPF in England and Wales.
The drug will be available on the same basis as Pirfendone so will provide an alternative therapy. It is already approved in Scotland.
APF contributed to the drug appraisal for both the Scottish Medicines Consortium (SMC) and NICE.
Professor Klaus Dugi, Medical Director and Managing Director, BI UK and Ireland who manufacture the drug said,
“This NICE recommendation for OFEV is very welcome news for patients in England and Wales who have this devastating disease, as it gives doctors a much needed new option in the management of IPF. At Boehringer Ingelheim, we have over 90 years of experience in the field of respiratory medicine and are delighted to be leading the way in bringing this novel medicine to people with IPF.”
Our Chairman Mike Bray says:
“Having been involved in the NICE appraisal process, Action for Pulmonary Fibrosis is very pleased that Nintedanib has been approved for the treatment of patients with IPF. With no cure and very limited treatment options, Nintedanib offers an alternative therapy which will be much welcomed by patients.”
The full advice can be found here: